FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG COA REDUCTASE INHIBITORS FOR THE INHIBITION FOR THE TREATMENT OF CANCER

摘要

This invention relates to pharmaceutical compositions for the treatment of abnormal cell growth, such as cancer or benign hyperproliferative disorder, in a mammal, which comprises a therapeutically effective amount of farnesyl transferase (Ftase) inhibitor in combination with an hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor and a pharmaceutically acceptable carrier.